IPO
I was struck recently by a piece in The Wall Street Journal by Pui-Wing Tam, The $1 Billion Club Gets Crowded, which highlights the amusing rate at which closely held, private US companies in the social media sector are garnering $1 billion-plus valuations. With 20 companies already fetching a 10-figure price tag— 15 of them since the beginning […]
Read MoreSeptember 15, 2011 source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]
Read MoreI will be moderating a panel, Venture Capitalists’ Best Practices on Commercializing Innovation at the Molecular Diagnostics World Congress on September 29, 2011 at the South San Francisco Conference Center. Here’s the panel topic summary, hope to see you there. Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get […]
Read MoreJune 22, 2011 source: Genetic Engineering and Biotechnology News On June 10, a day after withdrawing an $86 million IPO filed in November 2010, Ambit Biosciences reported securing $30 million in Series D-2 equity financing. “The terms currently obtainable in the public marketplace are not sufficiently attractive to the registrant to warrant proceeding with the […]
Read MoreMarch 2011 source: Financial Executives International (download a pdf reprint of the article) Over the years, venture capitalists have invested in clean technology and renewable energy with the expectation that returns will take a long time. The VCs were right. Development of technologies such as solar cell manufacturing, utility-scale renewable energy projects and genetically engineered […]
Read MoreFebruary 16, 2011 source: this guest blog post originally appeared on peHUB There has been a lot of buzz around highflying companies allowing sales of their stock on secondary trading platforms. There have always been opportunities for individual secondary sales in private companies but nothing to match the current level of action. Before, occasional private […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.